Pacific Biosciences of California (PACB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacific Biosciences of California (PACB) has a cash flow conversion efficiency ratio of -3.565x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.07 Million) by net assets ($5.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pacific Biosciences of California - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacific Biosciences of California's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Pacific Biosciences of California for a breakdown of total debt and financial obligations.
Pacific Biosciences of California Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacific Biosciences of California ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Doubledown Interactive Co Ltd
NASDAQ:DDI
|
0.044x |
|
BHG Group AB (publ)
ST:BHG
|
0.003x |
|
Shenmao Technology Inc
TW:3305
|
-0.070x |
|
Korea Electronic Power Industrial Development Co Ltd
KO:130660
|
0.072x |
|
Jiangsu Yabang Dyestuff Co Ltd
SHG:603188
|
-0.081x |
|
Advanced Power Electronics Corp
TW:8261
|
-0.011x |
|
Lihe Technology
SHE:300800
|
-0.005x |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
-0.363x |
Annual Cash Flow Conversion Efficiency for Pacific Biosciences of California (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacific Biosciences of California from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Pacific Biosciences of California market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.35 Million | $-111.21 Million | -20.791x | -5011.38% |
| 2024-12-31 | $506.59 Million | $-206.06 Million | -0.407x | -7.02% |
| 2023-12-31 | $701.30 Million | $-266.55 Million | -0.380x | +18.72% |
| 2022-12-31 | $562.90 Million | $-263.21 Million | -0.468x | -232.67% |
| 2021-12-31 | $790.99 Million | $-111.18 Million | -0.141x | -341.79% |
| 2020-12-31 | $335.49 Million | $19.50 Million | 0.058x | +104.08% |
| 2019-12-31 | $54.92 Million | $-78.31 Million | -1.426x | -144.85% |
| 2018-12-31 | $114.06 Million | $-66.43 Million | -0.582x | +25.73% |
| 2017-12-31 | $86.10 Million | $-67.52 Million | -0.784x | +2.26% |
| 2016-12-31 | $84.67 Million | $-67.93 Million | -0.802x | -23.20% |
| 2015-12-31 | $73.54 Million | $-47.89 Million | -0.651x | +30.48% |
| 2014-12-31 | $54.95 Million | $-51.47 Million | -0.937x | -117.20% |
| 2013-12-31 | $69.18 Million | $-29.83 Million | -0.431x | +38.60% |
| 2012-12-31 | $109.38 Million | $-76.82 Million | -0.702x | -30.59% |
| 2011-12-31 | $191.46 Million | $-102.97 Million | -0.538x | -23.38% |
| 2010-12-31 | $279.87 Million | $-122.00 Million | -0.436x | -203.17% |
| 2009-12-31 | $-177.12 Million | $-74.84 Million | 0.423x | +3.02% |
| 2008-12-31 | $-93.39 Million | $-38.30 Million | 0.410x | -- |
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more